Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Pancreatic Cancer
Both
Pancreatic Cancer
Trial Information
Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice
Inclusion Criteria:
- Adult patients, age >= 18 years
- Patients with metastatic pancreatic cancer where investigators have decided to give a
combination therapy Tarceva and gemcitabine according to Summary of Product
Characteristics (SmPC)
- Written and signed informed consent prior to onset of documentation
Exclusion Criteria:
- Contraindications for Tarceva according to Summary of Products Characteristics (SmPC)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Overall survival stratified by rash
Outcome Time Frame:
12 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Germany: Federal Institute for Drugs and Medical Devices (Bfarm)
Study ID:
ML23024
NCT ID:
NCT01782690
Start Date:
March 2012
Completion Date:
March 2015
Related Keywords:
- Pancreatic Cancer
- Pancreatic Neoplasms
Name | Location |
|---|
